Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Status of Claims
Claims 1-18 are now pending and will be examined on the merits herein.
Status of Claims
The amendments and arguments filed on 02/23/2026 are acknowledged and have been fully considered. Claims 1-4, 6-17, and 19 are now pending. Claims 5 and 18 are canceled; claims 1, 3, and 6 are amended; claim 19 is new.
Claims 1-4, 6-17, and 19 will be examined on the merits herein.
Objections/Rejections Withdrawn
Rejections and/or objections not reiterated from previous Office Actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied, and constitute the complete set presently being applied to the instant application.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(d):
(d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph:
Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
Claim 6 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. As benign prostate hyperplasia and prostatitis were listed as equivalent alternatives in claim 6 originally and with the amendment of 02/23/2026, benign prostate hyperplasia now a required limitation of claim 1, prostatitis is not further limiting the claim limitations. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements.
Claim Rejections - 35 USC § 103
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows:
1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.
Claims 1-4, 6-17, and 19 are rejected under 35 U.S.C. 103 as being unpatentable over Mishra (2013) in view of TW 202102245 A (Chi, 2021; machine translation provided by PE2E via FIT) and Tan (2017) as evidenced by Srivastava (2019).
In regards to claims 1-4, 8, 15, and 19, Mishra teaches a composition for treating bacteria that cause urinary tract infections comprising the extract of Artocarpus heterophyllus leaves (see Mishra, abstract; 2.1. collection of plants and preparation of extracts). As the composition is used for treating bacterial infections that cause urinary tract infections, the composition is understood as promoting urinary tract health using the broadest reasonable interpretation. The extract comprises dimethyl sulfoxide (i.e. an excipient) (see Mishra, 2.1. collection of plants and preparation of extracts). It is taught that the Artocarpus heterophyllus plant comprises artocarpin, artocapanone, and cycloartocarpanone as well as lupeol (see Srivastava, abstract; introduction; discussion, paragraph 1). It would be expected that the extract of the plant would comprise these components as well by one with ordinary skill in the art.
In regards to claims 6-7, it is taught that urinary tract infections lead to prostatitis (i.e., prostate inflammation) (see Mishra, page 348, column 2, paragraph 3). As such, it would be within the purview of one with ordinary skill in the art to treat a condition in a patient exhibiting prostatitis caused by a urinary tract infection by using the composition of Mishra.
The teachings of Mishra are silent on the composition being administered systemically or orally to a subject having benign prostate hyperplasia, the composition being combined with a food supplement or nutritional supplement, the excipient being artificial, and the subject of the administration being human. Mishra is also silent on the method of treating benign prostate hyperplasia wherein administering an extract of Artocarpus heterophyllus reduces one or more symptoms of benign prostate hyperplasia.
In regards to claims 1 and 14, Chi teaches a method of using Artocarpus heterophyllus extract in a food product for humans, specifically being combined with any edible material (see Chi, page 6, paragraphs 1-3).
In regards to claims 11-12, the composition is administered orally, which is understood to be a systemic method of administration of a drug (see Chi, page 5, paragraphs 1-2).
In regards to claim 16, it is taught that the extract is combined with various additives, such as Carbopol® (i.e., an artificial excipient).
In regards to claims 1 and 19, Tan teaches that it is plausible that benign prostate hyperplasia (BPH) causes urinary tract infections (UTIs) (i.e., UTIs are a symptom of BPH) (see Tan, page 2, Can BPH cause bladder infections in men).
In regards to claims 1-4, 6-8, 11-12, 14-17, and 19, it would have been prima facie obvious to a person of ordinary skill in the art, before the effective filing date of the claimed invention, to combine the teachings of Mishra with Chi and Tan to yield the method of the instant claims as both Mishra and Chi are drawn to methods of using an extract of Artocarpus heterophyllus. Further, as the teachings of Chi teach an edible or orally administered composition comprising the extract, it would be within the purview of one with ordinary skill in the art to combine the teachings of Chi and Mishra to formulate an edible or orally administered composition for treating urinary tract infections using the extract of Mishra. Further, as Tan teaches that BPH causes UTIs, it would be within the purview of one with ordinary skill in the art to use the composition of Mishra and Chi to treat subjects with BPH exhibiting the symptom of a UTI (in order to reduce the symptom). It would be obvious to one with ordinary skill in the art to combine the teachings of Mishra, Chi, and Tan according to the known method of creating an orally administered extract of Artocarpus heterophyllus (see Chi, page 6, final paragraph) to yield predictable results with a reasonable expectation of success. One with ordinary skill in the art would be motivated to combine prior art elements according to known methods to yield predictable results.
In regard to claims 9-10, as the combination of teachings of Mishra, Chi, and Tan would yield an identical composition as instantly claimed, the properties of the composition would be the same, such as the reduction of serum testosterone by the composition. "Products of identical chemical composition can not have mutually exclusive properties." In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658. As the prior art teaches an identical chemical structure, the properties applicant discloses and/or claims are necessarily present.
In regards to claim 13, it is further noted that the amount of drug is clearly a result effective variable that must be determined based on a variety of factors including the age, body weight, and health of the patient, the condition(s) to be treated and their severity, the route(s) of administration, the particular drug(s) used, adverse drug effects or toxicity, clinical response to treatment, etc., and is routinely optimized by the skilled artisan. Applicant is advised that recitation of dosages, without more, is generally insufficient to patentably distinguish over the prior art.
Response to Arguments
Applicant's arguments filed 02/23/2026 have been fully considered but they are not persuasive in view of the modified grounds of rejection as necessitated by amendment.
In regards to applicant’s argument that Mishra and Chi do not teach that the subject has benign prostate hyperplasia, however the rejection has been modified as necessitated by amendment to be over Mishra in view of Chi and Tan. The teachings of Tan have been described supra. As such, it would have been prima facie obvious to a person of ordinary skill in the art, before the effective filing date of the claimed invention, to combine the teachings of Mishra with Chi and Tan to yield the method of the instant claims as both Mishra and Chi are drawn to methods of using an extract of Artocarpus heterophyllus. Further, as the teachings of Chi teach an edible or orally administered composition comprising the extract, it would be within the purview of one with ordinary skill in the art to combine the teachings of Chi and Mishra to formulate an edible or orally administered composition for treating urinary tract infections using the extract of Mishra. Further, as Tan teaches that BPH causes UTIs, it would be within the purview of one with ordinary skill in the art to use the composition of Mishra and Chi to treat subjects with BPH exhibiting the symptom of a UTI (in order to reduce the symptom). It would be obvious to one with ordinary skill in the art to combine the teachings of Mishra, Chi, and Tan according to the known method of creating an orally administered extract of Artocarpus heterophyllus (see Chi, page 6, final paragraph) to yield predictable results with a reasonable expectation of success. One with ordinary skill in the art would be motivated to combine prior art elements according to known methods to yield predictable results.
Conclusion
No claims allowed.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to AYAAN A ALAM whose telephone number is (571)270-1213. The examiner can normally be reached M-F 8-5 EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bethany Barham can be reached at 571-272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/ISIS A GHALI/Primary Examiner, Art Unit 1611
/A.A.A./ Examiner, Art Unit 1611